Congratulations to Cold Spring Harbor Laboratory Director Dr. David Tuveson, who was elected to the National Academy of Medicine! He is being recognized for his ground-breaking work and leadership in the field of pancreatic cancer research. cshl.edu/david-tuveson-… #PancSM #PancChat

A much deserved congratulations to Dave! #TuvesonLab CSH Lustgarten Foundation cshl.edu/david-tuveson-…

1) PASS-01 #Pancreatic #Cancer Collective New Therapies /PASS-01 trial accruing! Amazingly successful at generating organoids/variations in sensitivity to panel of chemo/supported by Lustgarten Foundation & Stand Up To Cancer presented @ #SU2CSummit2023 Let's Win Pancreatic Cancer 💜 Pancreatic Cancer UK PanCAN

PASS-01 dream team working to improve #PDAC patient outcomes and revolutionize personalized medicine #Organoids Stand Up To Cancer #SU2CSummit2023 Grainne O'Kane #TuvesonLab

It’s a wrap on Day 1 of the #SU2CSummit2023! 💡 #StandUpToCancer scientists across the country have come to our annual conference to share their progress and discuss breakthroughs in cancer research.

#TuvesonLab human #organoid team is on the search for a new technician! Come join us in driving personalized medicine care for #pancreaticcancer schooljobs.com/careers/cshl/j…

I haven’t heard from a single person who now has a shorter/better commute. This is an overall failure - with politicians trying to mask it as a success. LIRR desperately needs to adjust the new schedule to help actual commuters.

“I just don’t see how we spend billions of dollars — I mean, billions of dollars — and anybody’s commute should be getting worse,” said Danielle Fugazy Scagliola, a Glen Cove City Council member who commutes to a job in Manhattan. “It’s unfathomable.” nytimes.com/2023/03/03/nyr…

Tested out LIRR GC over Penn this weekend - won’t ever do it again. Took 15 minutes of walking from the street to get to the train. The MTA video sped up is really demonstrating this is the best route . . . How did anyone think this was a good idea?

The LIRR's move to change eliminate most through service to Brooklyn-Atlantic Terminal has proven unpopular among LI commuters. While LIRR has made some adjustments that have helped, there are still major problems with the downgrade of Brooklyn service: thelirrtoday.com/2023/03/brookl…

Excited to be joining the American Cancer Society family and to advance therapy options for #PDAC patients! ACS Research Cold Spring Harbor Laboratory #postdoc #Organoids #PersonalizedMedicine #TuvesonLab

I can't stop staring at this map. There's a 20 year gap in life expectancy between deep red areas of the US, like the southeast, and blue areas like New England. Your lifespan in the US relates directly to where you live and how it's governed. latimes.com/business/story…

Our consortium white paper on patient-derived cancer models is now published! So many advances in how we study #cancer in the lab and important things to consider. #organoids mdpi.com/2072-6694/16/3…

PASS-01 trial #PDAC #ASCO24 ➡️rand ph2 mFFX vs.GnP ➡️WGS/RNA/PDO/CTCs/ctDNA ✅PP PFS 5.5 (GnP) vs. 4.0mths (mFFX) ➡️PP ❌gBRCA/PALB2 >KRASWT in GnP ➡️MTB directed 2nd line ➡️ GnP remains a backbone for drug dvp ➡️basal-like unmet need Proud Dr. Amber Habowski as translational leads

Day 3 poster session at #AACRPan24 featured two PASS-01 posters! Dr. Amber Habowski described preliminary results from #PDO work in the Tuveson lab, and Grainne O'Kane showed #genomic and #transcriptomic results in #pancreaticcancer patients. #PDAC

Extremely proud of the correlative work done by Dr. Amber Habowski from Cold Spring Harbor Laboratory on the Stand Up To Cancer - Lustgarten Foundation PASS-01 study; the results of which continue to provide a wealth of information for the treatment of #pancreaticcancer. #aacr25 #PDAC

Two important randomized trials in #PancreaticCancer published: 1st PASS-01 in metastatic cancer comparing FOLFIRINOX to Gem/Abraxane (Journal of Clinical Oncology) 2nd PREOPANC-2 in resectable/borderline resectable cancer comparing neoadjuvant FFX versus Gem/CRT (The Lancet Oncology) OncoAlert ⬇️

PASS-01:ph II mFFX v GnP;#PDAC denovo met ds; excl gBRCA/PALB2 ➡️no clinically sig diff GnP v mFFX ➡️basal-like poor OS-mPFS on mFFX 3 mths ➡️54% receive 2nd line; mOS<6mths ➡️PDOs/ctDNA to come Dr. Amber Habowski 1st-line biomarkers essential-RAS &🤞subtype doi.org/10.1200/JCO-25…